Pacira Pharmaceuticals, Inc. — Q1 2014 Form 10-Q Summary
Business Context and Reporting Period
Pacira is a specialty pharmaceutical company developing, manufacturing and commercializing products based on its DepoFoam drug-delivery technology. Commercial products were EXPAREL, launched in April 2012 for postsurgical analgesia, and DepoCyt(e), supplied to commercial partners for treatment of lymphomatous meningitis. The filing covers the unaudited three months ended March 31, 2014, compared with the three months ended March 31, 2013.
Financial Results and Key Metrics
| Metric | Q1 2014 | Q1 2013 | Change |
|---|---|---|---|
| Total revenue | $36.7 million | $11.6 million | +216% |
| EXPAREL net sales | $34.4 million | $10.4 million | +229% |
| DepoCyt(e) net sales | $1.3 million | $0.4 million | +240% |
| Gross profit | $18.5 million | $0.2 million | Material improvement |
| Gross margin | 50.6% | 1.7% | +48.9 percentage points |
| Loss from operations | $(9.3) million | $(18.6) million | Improved $9.4 million |
| Operating margin | (25.2%) | (160.9%) | Improved |
| Net loss | $(11.5) million | $(23.1) million | Improved $11.7 million |
| Net loss per share | $(0.34) | $(0.71) | Improved |
| Cash used in operations | $(4.7) million | $(13.8) million | Improved $9.1 million |
Calculated margins use reported revenue and expense figures. Cost of revenues was $18.1 million, up 59%, while research and development expense declined 12% to $5.2 million. Selling, general and administrative expense increased 75% to $22.6 million, including higher sales-force, promotional, educational and administrative spending. Stock-based compensation increased to $4.0 million from $2.2 million.
At March 31, 2014, cash and cash equivalents were $18.8 million and short-term investments were $45.8 million, for total cash and short-term investments of $64.6 million. Working capital was negative $23.1 million, primarily because the $120.0 million principal amount of convertible senior notes was classified as a current liability. Total assets were $163.7 million, total liabilities were $128.0 million and stockholders’ equity was $35.7 million.
Convertible senior notes had a net carrying value of $100.0 million and mature in 2019. The notes bear interest at 3.25%, with an effective interest rate of 7.22%. Including the royalty interest obligation, total debt and financing obligations were $101.1 million. The notes were convertible through June 30, 2014 because the stock-price conversion condition was met; management stated that it did not expect conversion because the notes’ market price exceeded estimated conversion value.
Material Changes Versus the Prior Comparable Period
- Revenue growth was driven primarily by EXPAREL adoption, including 346 new ordering accounts during the quarter. Cumulative EXPAREL ordering accounts reached 2,452, compared with 1,065 at the end of Q1 2013.
- Manufacturing utilization increased, reducing EXPAREL cost per unit and significantly improving gross margin.
- Operating and net losses narrowed despite substantially higher commercial investment.
- Research and development expense declined as pivotal clinical trials concluded, partially offset by product-development spending and higher stock-based compensation.
- Other expense declined to $2.2 million from $4.9 million because Q1 2014 had no debt-extinguishment loss; interest expense increased by $0.6 million.
- Operating cash use decreased substantially, while investing activities provided $9.0 million, primarily from net sales of short-term investments.
Guidance, Outlook, Risks and Unusual Items
- Management expected existing cash, short-term investments and product-sale revenue to fund operating expenses, capital expenditures and debt service for at least the next 12 months, but noted that additional financing may be required and is not assured on acceptable terms.
- Pacira planned to submit a supplemental FDA application in Q2 2014 for EXPAREL nerve-block indications, supported by femoral nerve-block efficacy and intercostal nerve-block safety data.
- The FDA approved an additional EXPAREL bulk-manufacturing suite in March 2014. A subsequent agreement with Patheon contemplated two dedicated U.K. manufacturing suites, with the first expected to begin commercial production in 2016 or 2017.
- On April 14, 2014, Pacira completed a public offering of 1.84 million shares at $64 per share, receiving approximately $110.4 million net proceeds.
- On April 28, 2014, Pacira expanded and extended its Mundipharma DepoCyte arrangements through June 2033 and expected approximately $8.0 million in non-refundable upfront payments, described elsewhere in the filing as approximately $7.5 million plus $0.5 million under separate agreements.
- Material business risks include dependence on EXPAREL and a limited customer base, concentration among wholesalers, reliance on single manufacturing sites and suppliers, regulatory and clinical approval risks, competition, intellectual-property protection, and continuing losses and negative operating cash flow.
- The three largest customers represented 84% of revenue in Q1 2014 and 77% in Q1 2013. Three customers represented 31%, 27% and 24% of accounts receivable at March 31, 2014.
- The company had no material litigation and reported no material changes to the risk factors in its 2013 Form 10-K. Lease commitments totaled $41.7 million, including the March 2014 headquarters lease extension through February 2028.
Most Important Facts for Investors to Verify
- Whether EXPAREL revenue growth and account expansion continue without disproportionate increases in selling, marketing and manufacturing costs.
- Whether improved gross margins translate into sustained operating-cash-flow improvement and eventual profitability.
- The conversion status and refinancing implications of the $120.0 million convertible notes, including future current-versus-long-term classification.
- The timing and outcome of the supplemental FDA application for nerve-block indications.
- The execution, cost and regulatory progress of the Patheon manufacturing expansion.
- The receipt, accounting treatment and durability of the Mundipharma upfront payments and expanded DepoCyte commercialization rights.
- Customer and product concentration, particularly the reliance on EXPAREL and three major customers.